COMPUMED, INC. ANNOUNCES INITIATION OF COVERAGE BY COHEN INDEPENDENT RESEARCH GROUP
LOS ANGELES, Jan 23, 2007 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company leading the development of advanced imaging technology for cost effective analysis and monitoring, today announced that Cohen Independent Research Group, a leading Wall Street research firm, has initiated coverage.
The OsteoGram system has applications across a broad spectrum of digital platforms, and was featured in conjunction with digital radiography (DR), computed radiography (CR) and digital mammography systems from CompuMed licensing partners including the Eastman Kodak Company, Fujifilm Medical Systems USA and Swissray International.
The report concludes, "CompuMed's unique business model coupled with its aggressive expansion plans provides a strong outlook for investors."
The complete 160-page report is available at www.cohenresearch.com.
"We are very pleased to have a leading research firm, such as Cohen Independent Research, initiate coverage on CompuMed after an extensive analysis of our business," said CEO, Jerry McLaughlin. "This thorough report will provide the financial sector with valuable insight into our opportunities, business strategy and the markets we have before us."
About Cohen Independent Research Group:
Cohen Independent Research Group (CIRG) is a leading Wall Street research firm. CIRG provides and distributes Wall Street research-analyst coverage for a select group of companies with outstanding business models. CIRG distributes in-depth stock market research reports that highlight the company's market opportunity, technology, management, competition and other key differentiators that may affect their short and long term valuation. Visit CIRG at www.cohenresearch.com.
About CompuMed:
Founded in 1973, CompuMed, Inc. (CMPD.OB) is leading the development of advanced imaging and medical informatics solutions that provide cost effective analysis and monitoring. CompuMed focuses on cardiovascular and musculoskeletal diseases, as well as other diseases associated with aging populations. Its unique expertise in telemonitoring, imaging and analysis facilitates the development of new solutions and services designed to improve healthcare provider workflow and patient care, while reducing costs. CompuMed's core products, the OsteoGramŽ and CardioGramTM systems, are cleared by the FDA and reimbursable by Medicare. The OsteoGram is an accurate and precise technology for osteoporosis testing. The underlying OsteoGram technology has significant cost advantages over other technologies and will be applied to a suite of value-added applications, such as following the progression of arthritic disease and diagnosing vertebral fractures and scoliosis. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms, and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within two minutes of receipt, and has the additional capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning CompuMed's plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission. All such forward-looking statements are expressly qualified by these cautionary statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
CONTACT: Susan Tellem - Tellem Worldwide, +1 (310) 479-6111 x.16.